Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

myeloproliferative neoplasm News | Kisho

Kisho

Not rare diseases news,
news about your rare disease.

Earlier

A retrospective study examines the clinical characteristics of patients with both chronic myeloid leukemia and BCR::ABL1 negative myeloproliferative neoplasms. The findings contribute to understanding the complexities of these coexisting conditions.

A pilot trial investigates thromboprophylaxis using apixaban versus aspirin in patients with JAK2-positive myeloproliferative neoplasms. This research aims to improve treatment strategies for this rare disease.

A recent study published in PubMed examines real-world outcomes for patients with acute myeloid leukemia following myeloproliferative neoplasms in the U.S. This research highlights the evolving treatment landscape and its impact on patient outcomes.

A prospective observational study in Japan, MPN-15, evaluates the prognosis of patients with myeloproliferative neoplasms. The baseline analysis provides critical insights into patient outcomes and disease progression.

Not rare diseases news,news about your rare disease.

Earlier

A retrospective study examines the clinical characteristics of patients with both chronic myeloid leukemia and BCR::ABL1 negative myeloproliferative neoplasms. The findings contribute to understanding the complexities of these coexisting conditions.

A pilot trial investigates thromboprophylaxis using apixaban versus aspirin in patients with JAK2-positive myeloproliferative neoplasms. This research aims to improve treatment strategies for this rare disease.

A recent study published in PubMed examines real-world outcomes for patients with acute myeloid leukemia following myeloproliferative neoplasms in the U.S. This research highlights the evolving treatment landscape and its impact on patient outcomes.

A prospective observational study in Japan, MPN-15, evaluates the prognosis of patients with myeloproliferative neoplasms. The baseline analysis provides critical insights into patient outcomes and disease progression.

Not rare diseases news,
news about your rare disease.